Advisors Asset Management Inc. lifted its holdings in shares of The Chemours Company (NYSE:CC - Free Report) by 65.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 390,095 shares of the specialty chemicals company's stock after acquiring an additional 154,857 shares during the period. Advisors Asset Management Inc. owned 0.26% of Chemours worth $5,278,000 at the end of the most recent reporting period.
A number of other hedge funds have also modified their holdings of the business. Royal Bank of Canada grew its position in shares of Chemours by 6.8% during the first quarter. Royal Bank of Canada now owns 585,702 shares of the specialty chemicals company's stock worth $7,926,000 after acquiring an additional 37,382 shares during the last quarter. Quarry LP purchased a new position in Chemours in the 1st quarter valued at $95,000. Baird Financial Group Inc. purchased a new position in Chemours in the 1st quarter valued at $148,000. State of Wyoming grew its position in Chemours by 13.4% in the 1st quarter. State of Wyoming now owns 13,978 shares of the specialty chemicals company's stock valued at $189,000 after buying an additional 1,657 shares during the last quarter. Finally, Landscape Capital Management L.L.C. grew its position in Chemours by 34.4% in the 1st quarter. Landscape Capital Management L.L.C. now owns 47,075 shares of the specialty chemicals company's stock valued at $637,000 after buying an additional 12,043 shares during the last quarter. 76.26% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of equities analysts recently weighed in on the stock. Wall Street Zen lowered shares of Chemours from a "hold" rating to a "sell" rating in a research report on Wednesday, May 21st. Barclays reduced their target price on Chemours from $16.00 to $13.00 and set an "equal weight" rating for the company in a report on Wednesday, May 28th. Mizuho lifted their price target on Chemours from $13.00 to $16.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 15th. The Goldman Sachs Group cut their price target on Chemours from $21.00 to $14.00 and set a "neutral" rating for the company in a research note on Wednesday, May 14th. Finally, Royal Bank Of Canada lifted their price target on Chemours from $14.00 to $15.00 and gave the stock an "outperform" rating in a research note on Thursday, July 3rd. Five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $17.38.
Get Our Latest Report on CC
Insider Activity at Chemours
In related news, CEO Denise Dignam acquired 4,068 shares of the company's stock in a transaction dated Friday, August 8th. The stock was bought at an average price of $12.06 per share, with a total value of $49,060.08. Following the purchase, the chief executive officer directly owned 191,546 shares in the company, valued at $2,310,044.76. The trade was a 2.17% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.34% of the stock is currently owned by corporate insiders.
Chemours Trading Down 1.3%
Shares of NYSE CC traded down $0.23 on Wednesday, reaching $16.45. 996,162 shares of the company traded hands, compared to its average volume of 3,527,075. The Chemours Company has a fifty-two week low of $9.13 and a fifty-two week high of $22.38. The company has a 50 day moving average of $13.91 and a 200 day moving average of $12.74. The company has a current ratio of 1.68, a quick ratio of 0.83 and a debt-to-equity ratio of 17.16. The stock has a market capitalization of $2.46 billion, a PE ratio of -5.87 and a beta of 1.61.
Chemours (NYSE:CC - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The specialty chemicals company reported $0.58 EPS for the quarter, beating analysts' consensus estimates of $0.46 by $0.12. Chemours had a negative net margin of 7.19% and a positive return on equity of 35.14%. The company had revenue of $1.62 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter in the prior year, the company posted $0.38 EPS. The company's quarterly revenue was up 5.0% compared to the same quarter last year. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities research analysts forecast that The Chemours Company will post 2.03 earnings per share for the current fiscal year.
Chemours Cuts Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 12th. Stockholders of record on Friday, August 15th will be paid a dividend of $0.0875 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $0.35 dividend on an annualized basis and a dividend yield of 2.1%. Chemours's dividend payout ratio is currently -12.50%.
Chemours Profile
(
Free Report)
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.
See Also

Before you consider Chemours, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.
While Chemours currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.